NCT06283459View on ClinicalTrials.gov

Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 4, 2024

Primary Completion Date

March 7, 2025

Study Completion Date

March 7, 2025

Conditions
SARS CoV 2 Infection
Interventions
BIOLOGICAL

IMNN-101

IMNN-101 is a DNA vaccine encoding SARS-CoV-2 Omicron XBB.1.5 spike antigen. The drug product is a suspension of the DNA plasmid formulated with the facilitating agent, bis-(aza-18-crown-6)-poloxamer (Crown poloxamer, CP), and adjuvant AlPO4.

Trial Locations (2)

19107

DM Clinical Research, Philadelphia

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Lead Sponsor

Imunon
All Listed Sponsors
lead

Imunon

INDUSTRY

NCT06283459 - Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2 | Biotech Hunter | Biotech Hunter